Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cultured bacteria isolated from primary sclerosing cholangitis patient bile induce inflammation and cell death.

mSphere·2025
Same author

Layilin inhibits integrin activation, and its loss results in platelet hyperactivation via Rac1 in inflammatory bowel disease.

Blood·2025
Same author

Restricting metabolic plasticity enhances stress adaptation through the modulation of PDH and HIF1A in TRAP1-depleted colon cancer.

Cancer letters·2025
Same author

A glycan atlas of the mammalian intestine through ontogeny and inflammation.

bioRxiv : the preprint server for biology·2025
Same author

The Utility of the Immunoglobulin A Flag Used in Celiac Disease Serology Testing on a Particle-Based Multianalyte Technology Platform.

Clinical chemistry·2025
Same author

A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024

Related Experiment Video

Updated: May 5, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K

Sargramostim for active Crohn's disease.

Joshua R Korzenik1, Brian K Dieckgraefe, John F Valentine

  • 1Inflammatory Bowel Disease Center, Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA. jkorzenik@partners.org

The New England Journal of Medicine
|May 27, 2005
PubMed
Summary
This summary is machine-generated.

Sargramostim (granulocyte-macrophage colony-stimulating factor) did not meet its primary goal for Crohn's disease treatment. However, it showed significant improvements in secondary measures, including disease remission and quality of life.

More Related Videos

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

11.7K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K

Related Experiment Videos

Last Updated: May 5, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K
Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

11.7K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Sargramostim, a hematopoietic growth factor, stimulates innate immune cells in the gut.
  • Preliminary research indicated potential efficacy of sargramostim in Crohn's disease management.
  • A randomized, placebo-controlled trial was designed to investigate this therapeutic possibility.

Purpose of the Study:

  • To evaluate sargramostim as a novel therapeutic agent for moderate-to-severe active Crohn's disease.
  • To assess the impact of sargramostim on clinical response, disease severity, and quality of life.
  • To compare the efficacy and safety of sargramostim versus placebo in Crohn's disease patients.

Main Methods:

  • 124 patients with active Crohn's disease were randomized in a 2:1 ratio to receive sargramostim (6 mug/kg/day) or placebo subcutaneously for 56 days.
  • Immunosuppressants and glucocorticoids were prohibited; antibiotics and aminosalicylates were permitted.
  • The primary endpoint was a clinical response (≥70-point decrease in CDAI score at day 57); secondary endpoints included changes in disease severity, quality of life, and adverse events.

Main Results:

  • No significant difference was observed in the primary endpoint of clinical response (≥70-point CDAI decrease) between groups (54% vs. 44%, P=0.28).
  • Sargramostim group showed significantly higher rates of a ≥100-point CDAI decrease (48% vs. 26%, P=0.01) and remission (CDAI ≤150) (40% vs. 19%, P=0.01) at day 57.
  • Improvements in quality of life and sustained clinical response/remission rates were noted in the sargramostim group; mild-to-moderate injection site reactions and bone pain were more frequent.

Conclusions:

  • While the primary endpoint was not met, sargramostim therapy demonstrated significant benefits in secondary endpoints for active Crohn's disease.
  • Findings suggest sargramostim may decrease disease severity and enhance quality of life in patients with Crohn's disease.
  • Further research may explore optimized dosing or patient selection for sargramostim in Crohn's disease treatment.